- Home
- TWLO vs BIIB Comparison
TWLO vs BIIB Comparison
Compare TWLO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWLO
- BIIB
- Stock Information
- Founded
- TWLO 2008
- BIIB 1978
- Country
- TWLO United States
- BIIB United States
- Employees
- TWLO N/A
- BIIB N/A
- Industry
- TWLO Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TWLO Technology
- BIIB Health Care
- Exchange
- TWLO Nasdaq
- BIIB Nasdaq
- Market Cap
- TWLO 18.1B
- BIIB 19.9B
- IPO Year
- TWLO 2016
- BIIB 1991
- Fundamental
- Price
- TWLO $117.63
- BIIB $131.20
- Analyst Decision
- TWLO Buy
- BIIB Buy
- Analyst Count
- TWLO 25
- BIIB 26
- Target Price
- TWLO $129.16
- BIIB $194.95
- AVG Volume (30 Days)
- TWLO 2.9M
- BIIB 1.7M
- Earning Date
- TWLO 05-01-2025
- BIIB 05-01-2025
- Dividend Yield
- TWLO N/A
- BIIB N/A
- EPS Growth
- TWLO N/A
- BIIB 26.39
- EPS
- TWLO N/A
- BIIB 10.12
- Revenue
- TWLO $4,583,449,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TWLO $10.61
- BIIB N/A
- Revenue Next Year
- TWLO $8.01
- BIIB N/A
- P/E Ratio
- TWLO N/A
- BIIB $12.83
- Revenue Growth
- TWLO 9.28
- BIIB 1.59
- 52 Week Low
- TWLO $52.51
- BIIB $110.04
- 52 Week High
- TWLO $151.95
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TWLO 66.89
- BIIB 59.82
- Support Level
- TWLO $112.69
- BIIB $123.97
- Resistance Level
- TWLO $119.52
- BIIB $132.94
- Average True Range (ATR)
- TWLO 3.01
- BIIB 3.49
- MACD
- TWLO 0.08
- BIIB 1.04
- Stochastic Oscillator
- TWLO 82.72
- BIIB 88.37
About TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.